The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

Highlights • HCV core antigen in monitoring antiviral therapy. • Telaprevir therapy in patients infected with HCV genotype1. • Predictive factors of sustained virological response (SVR) in new DAA treatment.

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2015-08, Vol.69, p.68-73
Main Authors: Garbuglia, Anna Rosa, Lionetti, Raffaella, Lapa, Daniele, Taibi, Chiara, Visco-Comandini, Ubaldo, Montalbano, Marzia, D'Offizi, Gianpiero, Castiglione, Filippo, Capobianchi, Maria Rosaria, Paci, Paola
Format: Article
Language:English
Subjects:
Aged
Allergy and Immunology
Antigens, Viral - blood
Antiviral Agents - therapeutic use
Drug Therapy, Combination
EVRearly virological response
Female
Genotype
HCVcore antigen
Hepacivirus - genetics
Hepacivirus - immunology
Hepacivirus - isolation & purification
Hepatitis C virus
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Infectious Disease
Interferon-alpha - therapeutic use
Male
Middle Aged
Nuclear polyhedrosis virus
Oligopeptides - therapeutic use
Predictive Value of Tests
Prospective Studies
Ribavirin - therapeutic use
RNA, Viral - blood
ROC Curve
RVRrapid virological response
Sensitivity and Specificity
SVRsustained virological response
Telaprevir
Viral Core Proteins - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • HCV core antigen in monitoring antiviral therapy. • Telaprevir therapy in patients infected with HCV genotype1. • Predictive factors of sustained virological response (SVR) in new DAA treatment.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2015.06.002